Prelude Therapeutics Incorporated
PRLD
$5.55
$0.193.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 55.43% | 67.63% | 42.72% | 38.88% | 10.10% |
| Total Depreciation and Amortization | -18.48% | -10.11% | -14.52% | 4.94% | -4.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -47.19% | -53.46% | -36.47% | -49.90% | -22.84% |
| Change in Net Operating Assets | -656.16% | -99.10% | 765.83% | -175.67% | -87.82% |
| Cash from Operations | 40.27% | 36.65% | 211.45% | 29.97% | -13.09% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 94.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -667.57% | -86.34% | -372.15% | 271.35% | -56.41% |
| Cash from Investing | -668.55% | -86.33% | -372.80% | 273.53% | -55.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 100.00% | 44.79% |
| Issuance of Common Stock | 97,943.48% | -- | 20,020.16% | -100.00% | -64.20% |
| Repurchase of Common Stock | -550.00% | -920.00% | 28.57% | 61.54% | 88.89% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 231,845.95% | -96.25% | 73,464.71% | 96.18% | -37.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 132.67% | -148.57% | -1,016.12% | 225.62% | -565.14% |